Pyruvate Kinase Deficiency: A Real Option With an Honest Response Rate, on a Real Timeline
A single patient, a decade into a transfusion schedule she has never controlled. The disagreement isn't whether mitapivat might help — it's whether now is the right moment to find out.
Bianca F. works as a veterinary technician at a busy small-animal practice, a job physical enough that her chronic fatigue has started showing up in ways her coworkers notice before she does, and is eight months from a wedding she has been planning around her transfusion schedule rather than the other way around — her venue deposit and her infusion center's calendar were compared line by line before either was finalized. Her pyruvate kinase deficiency was diagnosed in childhood, genetically confirmed as compound heterozygous for two pathogenic PKLR variants, one of them a missense change other than R479H, and she underwent splenectomy at sixteen for partial benefit — her hemolysis slowed but never stopped, and she has needed a red cell transfusion every six to eight weeks ever since, now going on a decade. Her scleral icterus and the mild hepatomegaly on her last exam are both longstanding findings, unchanged from prior visits, rather than anything acutely new.
Mitapivat, a pyruvate kinase activator, offers the first disease-targeted therapy this condition has ever had, rather than the supportive measures — transfusion, splenectomy, chelation — that have defined its management for decades. But the trial data that matter most for her specifically come from ACTIVATE-T, the study conducted in transfusion-dependent patients rather than ACTIVATE's non-transfusion-dependent population, and ACTIVATE-T's own response rate was real but far from universal: ten of twenty-seven patients, thirty-seven percent, reached the primary endpoint of a thirty-three percent or greater cut in transfusion burden, and six, twenty-two percent, became transfusion-free. Her prior splenectomy is not what decides whether she is one of them — ACTIVATE-T enrolled splenectomized patients and excluded only splenectomy within the preceding year. What the trial did require, and what actually separates responders from non-responders, is genotype: two mutant PKLR alleles with at least one non-R479H missense variant, since patients homozygous for R479H or for non-missense variants have consistently failed to respond. Her missense allele is the reason she sits inside the population ACTIVATE-T studied rather than the one it could not help.
A real option with an honest response rate, on a real timeline
I'd offer her a trial of mitapivat — it's the first disease-targeted option this condition has had, and ACTIVATE-T specifically enrolled transfusion-dependent patients like her, not just the milder non-transfusion-dependent population. A real chance at reducing her transfusion burden is worth the trial, especially given how much of her life she's currently scheduling around it.
I want to state the response rate honestly rather than oversell it: ACTIVATE-T's primary endpoint was met by ten of twenty-seven patients, thirty-seven percent, with six becoming transfusion-free. Better than nothing by a wide margin, but not a guarantee, and I'd say that number to her in those words.
That honest framing is exactly why I'd be more cautious given her timeline, and I want to be precise that my objection isn't her spleen. Mitapivat activates the mutant enzyme itself and restores red-cell ATP; it doesn't work by sparing the spleen, and ACTIVATE-T enrolled splenectomized patients specifically. My objection is the schedule. ACTIVATE-T ran a sixteen-week individualized dose-optimisation period before a twenty-four-week fixed-dose period — roughly forty weeks before anyone could say whether a patient had responded. She has thirty-five. Starting now means she is still titrating, or newly at fixed dose, in the weeks around the wedding she has spent two years scheduling around her infusions.
I'm not arguing against ever trying mitapivat — only against starting it now, this close to a date she's built her life around, rather than after the wedding when a non-response wouldn't collide with it.
Agreed, after Bianca weighed in directly, to start mitapivat now rather than after the wedding — her own preference was to know sooner rather than later whether it would help, and to keep her existing transfusion schedule as a safety net throughout the trial period regardless of early response.
Not agreed: how many weeks of trial to allow before calling it a non-response given ACTIVATE-T's own response timeline — left as a decision for a follow-up visit once her early labs are in hand.